Intensive insulin regimens have been shown to delay the progression of complications associated with untreated or poorly treated type 1 diabetes (T1D). Therefore, it is unsurprising that insulins continue to dominate the T1D market; they are the primary treatment option for disease management. Long-acting and rapid-acting insulins are the patient-share leaders in the United States. Differences exist in the choice of branded insulin, choice of regimen, and order in which brands and/or regimens are prescribed. In addition, biosimilar insulins have added a layer of complexity to the T1D therapy market. The increasing use of insulin pumps is also playing a role in the evolving T1D market.
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
Markets covered: United States
Key companies: Novo Nordisk, Sanofi, Eli Lilly
Key drugs: Lyumjev, Lantus, Levemir, Toujeo, Apidra, NovoLog, Fiasp, Humalog, Admelog, Basaglar
The Treatment Algorithms dashboard is an interactive supplement to our PowerPoint-based claims data analysis reports and retains the full set of analyses included in the reports (i.e., newly diagnosed patients, recently treated patients, persistency, and compliance). The dashboard allows for easier navigation of data visualizations and provides more detailed analyses examining the flow of treatment regimens in newly diagnosed and recently treated patients.